TALZENNA Drug Patent Profile

When do Talzenna patents expire, and what generic alternatives are available?

Talzenna is a drug marketed by Pfizer and is included in two NDAs. There are six patents protecting this drug.

This drug has ninety-seven patent family members in thirty-two countries.

The generic ingredient in TALZENNA is talazoparib tosylate. Two suppliers are listed for this compound. Additional details are available on the talazoparib tosylate profile page.

DrugPatentWatch^® Generic Entry Outlook for Talzenna

Talzenna was eligible for patent challenges on October 16, 2022.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be October 20, 2031. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for TALZENNA

International Patents:	97
US Patents:	6
Applicants:	1
NDAs:	2

US Patents and Regulatory Information for TALZENNA

TALZENNA is protected by six US patents and one FDA Regulatory Exclusivity.

This potential generic entry date is based on patent 8,735,392.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	217439-006	Mar 7, 2024		RX	Yes	Yes	9,820,985
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-003	Sep 20, 2021		DISCN	Yes	No	9,820,985
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-006	Jun 20, 2023		DISCN	Yes	No	8,735,392		Y	Y
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	217439-004	Mar 7, 2024		RX	Yes	No	9,820,985
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	217439-005	Mar 7, 2024		RX	Yes	No	10,780,088
Pfizer	TALZENNA	talazoparib tosylate	CAPSULE;ORAL	211651-003	Sep 20, 2021		DISCN	Yes	No	10,189,837		Y	Y

International Patents for TALZENNA

When does loss-of-exclusivity occur for TALZENNA?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Argentina

Australia

Brazil

Canada

China

Cyprus

Denmark

European Patent Office

Hungary

Israel

Japan

Mexico

New Zealand

Poland

Portugal

Russian Federation

Singapore

Slovenia

South Africa

South Korea

Spain

Taiwan

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering TALZENNA around the world.

Country	Patent Number	Title	Estimated Expiration
Argentina	083502	SAL TOSILADA DE (8S,9R)-5-FLUORO-8-(4-FLUOROFENIL)-9-(1-METIL-1H-1,2,4-TRIAZOL-5-IL)-8,9-DIHIDRO-2H-PIRIDO[4,3,2-DE]FTALAZIN-3(7H)-ONA CRISTALINA
Australia	2011317040	Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt
Australia	2017201564	CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT
Brazil	112013009117	sal tosilato de (8s,9r)-5-fluor-8-(4-fluorefenil)-9-(1-metil-1h-1,2,4-triazol-5-il)-8,9-diidro-2h-pirido[4,3,2-de]ftalazin-3(7h)-ona, método para preparar uma forma cristalina e uso do mesmo,composição farmacêutica e método para tratar um câncer ou um sintoma do mesmo.
Canada	2814581	SEL TOSYLATE DE LA (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H- 1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTALAZIN-3(7H)-ONE CRISTALLIN (CRYSTALLINE (8S,9R)-5-FLUORO-8-(4-FLUOROPHENYL)-9-(1-METHYL-1H-1,2,4-TRIAZOL-5-YL)-8,9-DIHYDRO-2H-PYRIDO[4,3,2-DE]PHTHALAZIN-3(7H)-ONE TOSYLATE SALT)
China	103282365	结晶的(8S,9R)‑5‑氟‑8‑(4‑氟苯基)‑9‑(1‑甲基‑1H‑1,2,4‑三唑‑5‑基)‑8,9‑二氢‑2H‑吡啶并[4,3,2‑de]酞嗪‑3(7H)‑酮甲苯磺酸盐 (Crystalline (8S,9R)--fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt)

Supplementary Protection Certificates for TALZENNA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2767537	C20190041 00311	Estonia		PRODUCT NAME: TALASOPARIIB;REG NO/DATE: EU/1/19/1377 24.06.2019
2767537	756	Finland
2767537	C02767537/01	Switzerland		FORMER OWNER: MEDIVATION TECHNOLOGIES LLC, US
2767537	408 19-2019	Slovakia		OWNER(S): MEDIVATION TECHNOLOGIES LLC, NEW YORK, NY, US; DATUM ZAPISU DO REGISTRA: 20.1.2022
2767537	2019/060	Ireland		PRODUCT NAME: TALAZOPARIB, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT.; NAT REGISTRATION NO/DATE: EU/1/19/1377/001 EU/1/19/1377/006 20190620; FIRST REGISTRATION NO/DATE: EU/1/19/1377/001 EU/1/19/1377/006 20190620 (20200708)
2767537	C201930072	Spain		PRODUCT NAME: TALAZOPARIB, OPCIONALMENTE EN FORMA DE SAL FARMACEUTICAMENTE ACEPTABLE; NATIONAL AUTHORISATION NUMBER: EU/1/19/1377; DATE OF AUTHORISATION: 20190620; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/19/1377; DATE OF FIRST AUTHORISATION IN EEA: 20190620

TALZENNA (talazoparib) Investment Fundamentals, Exclusivity Timeline, Patent Estate Strength, and Generic/Biosimilar Risk

Last updated: July 8, 2026

Talzenna (talazoparib) is a PARP inhibitor with a concentrated IP moat anchored by drug-substance and polymorph/formulation patents plus method-of-use claims tied to BRCA-mutated breast cancer and other HRR-deficient indications. Investment exposure is dominated by (1) U.S. exclusivity and patent expiration cadence, (2) label expansion versus competing PARP inhibitors, (3) payer access dynamics for monotherapy, and (4) defensibility against generic entry after Orange Book protection ends. Key risk is accelerated erosion of PARP share by competitive sequencing, combination uptake, and price pressure as newer agents gain formulary positions.

---

What are Talzenna (talazoparib) the key investment drivers for 2026 and beyond?

Revenue and demand fundamentals investors track

Investment underwriting for Talzenna typically hinges on:

• U.S. and ex-U.S. net sales trajectory tied to incident populations in germline/HRR-mutated cancers and uptake among oncologists for metastatic, advanced, or treatment-line-appropriate settings.
• Net price and rebate rate movement driven by:
  • PARP class competition (head-to-head pricing pressure).
  • Manufacturer-payer contracting terms.
  • Medicare Part D dynamics for oncology drugs where applicable.
• Share durability versus PARP competitors by:
  • Dosing convenience (oral, fixed dosing).
  • Tolerability profile and AE management practices (anemia, thrombocytopenia monitoring).
  • Evidence strength for specific tumor subgroups and prior-therapy contexts.

Clinical and label-extension catalysts

Talazoparib’s commercialization durability depends on whether incremental trials:

• Expand or deepen biomarker-defined subgroups (germline vs somatic BRCA, HRR deficiency breadth).
• Improve positioning in earlier lines, including combination use where PARP inhibitors gain shelf space through guideline adoption.
• Reduce barriers to uptake via tolerability improvements or refined dose-modification protocols.

Capital-market sensitivities

Investors usually model Talzenna on:

• Product lifecycle risk as U.S. patent and exclusivity windows close.
• Litigation calendar and potential settlement terms that can shift generic entry timing.
• Margin pressure from:
  • Increased field activity and contracting costs.
  • Loss of exclusivity protections across dosage forms or route-specific claims.

---

What patent estate protects Talzenna (talazoparib) in the U.S., and how strong is it?

Core patent layers investors should map

A defensible Talzenna estate usually includes:

1. Drug substance patents covering talazoparib and its key chemical forms.
2. Composition/formulation patents covering specific solid forms, polymorphs, particle size, excipient systems, and stability or dissolution targets.
3. Method-of-use patents tied to treating BRCA-mutated or HRR-deficient cancers with defined dosing regimens.
4. Potential secondary patents tied to manufacturing processes or improvements.

How to read strength signals

The strength of the Talzenna estate is typically highest where:

• There are multiple, independently enforceable composition and method-of-use listings.
• The method-of-use claims align closely with the FDA-approved label so that generic labeling triggers infringement risk.
• There is no easy “design-around” route (for example, claim scope is not limited to narrow excipient or dosing parameters).

Patent estate strength bottom line: For PARP inhibitors like talazoparib, the highest litigation leverage tends to sit in method-of-use and formulation claims listed in the Orange Book, since generic entrants must avoid infringement while also meeting FDA labeling and bioequivalence requirements. The practical barrier is the number of expiring claims that remain enforceable near launch windows.

---

When does Talzenna lose U.S. exclusivity, and what are the key expiration dates?

Exclusivity vs patent term

Investment models should separate:

• Regulatory exclusivity (including U.S. new chemical entity exclusivity, if applicable to talazoparib’s approval pathway).
• Patent expiration of the Orange Book-listed patents.
• Potential pediatric exclusivity extensions where triggered.
• “Last protected use” where method-of-use patents extend the time generics can launch without carve-outs.

Decision-useful modeling approach

• Build a launch-risk calendar based on:
  • Each Orange Book-listed patent’s statutory expiration.
  • Any listed patent term adjustments.
  • Expiration order (drug substance first vs formulation vs method-of-use later).
• Then overlay litigation outcomes:
  • Dismissals and reversals can shift entry timing by years.
  • Settlement agreements can create authorized generic or “carve-out” timelines.

Net investor takeaway: Talzenna’s generic threat timing is driven less by single patent expiry and more by the “stack” of simultaneously enforceable patents listed for the commercial dosage form(s) and indications.

---

What generic entry risks exist for Talzenna (talazoparib) in the U.S.?

Paragraph IV and ANDA entry framework

Generic entry risk rises when:

• An ANDA filer files a Paragraph IV certification challenging one or more Orange Book-listed patents.
• The challenged patents align with the commercial product’s active ingredient, strength, and dosage form.
• Infringement arguments are strong due to label-matching or dosing regimen claim coverage.

What investors should model for ANDA scenarios

Generic entry outcomes commonly fall into three categories:

• Early resolution with potential launch at risk if the court invalidates or finds non-infringement.
• Settlement leading to delayed launch (often with an end date tied to dismissal or covenant conditions).
• Carve-out strategy where the generic attempts to avoid infringement by narrowing label. That can reduce sales impact depending on whether the carved-out indications are material to Talzenna’s revenue.

Key risk lens: If Talzenna’s method-of-use and formulation listings remain intact near the end of patent life, ANDA filers face a longer path to full-label substitution. That delays price erosion.

---

What patent litigation affects Talzenna (talazoparib), and how does it change launch timing?

Litigation levers that matter

• Who the plaintiffs and defendants are in Paragraph IV actions.
• Which patents are asserted and how many are upheld or dismissed.
• Whether settlements include:
  • Exclusivity/restriction periods for first generic.
  • Authorized generic provisions.
  • Country-by-country terms for distribution rights and launch schedules.

How litigation translates into financial outcomes

• Prolonged injunction or appeal windows can delay generic entry, protecting revenue and valuation.
• Settlement can cap downside by creating a known entry date.
• Adverse court outcomes can shift from “delayed risk” to “accelerated risk” quickly, compressing remaining value.

Investment conclusion on litigation: For Talzenna, the financial magnitude comes from whether litigation resolves before key patent expirations. If it does not, investors still price the generic risk into the tail end of the patent stack.

---

What is the Orange Book status of Talzenna (talazoparib) and what does it imply for generic competition?

Orange Book information investors use

For each talazoparib dosage form/strength, investors map:

• Orange Book-listed patent numbers.
• Proprietary names and application holders.
• Patent expiration dates for each listing.
• Listing type (drug substance, drug product, method of use).
• Status changes over time (including additions or deletions).

Implication for market structure

• High listing counts near the end of term usually extend “full market substitution” beyond the first patent expiry.
• Method-of-use listings can block “label-equivalent” substitution even when composition/formulation protection ends.

Bottom line: Orange Book stacking directly affects probability-weighted generic launch timing and the expected magnitude of price erosion.

---

How does Talzenna (talazoparib) compare with other PARP inhibitors on exclusivity risk and competitive positioning?

Competitive landscape within PARP class

Talzenna competes with other PARP inhibitors that may differ in:

• Line-of-therapy evidence and guideline placement.
• Combination regimen adoption rates.
• Safety monitoring burdens and dose management patterns.
• Stakeholder preference based on trial design, endpoints, and patient selection.

Investment relevance of “competitive shelf life”

Even if Talzenna has a strong patent position, competitive uptake can shift revenue away from it. Conversely, even with patent risk, continued preference by prescribers can slow net sales decline after generics arrive due to:

• Patient-specific responses.
• Institutional formularies.
• Contracting inertia.

Comparison takeaway: A favorable Talzenna investment profile requires both patent-driven protection and sustained clinical positioning against PARP peers.

---

What dosage forms and formulations are protected for Talzenna (talazoparib)?

Formulation/IP hotspots

Formulation protection typically clusters around:

• Solid-state form (including polymorph).
• Release and dissolution characteristics.
• Stability and shelf-life performance.
• Manufacturing process controls affecting impurity profiles and bioavailability.

Why formulation patents matter economically

Formulation patents can:

• Delay generic substitution even when API substance protection weakens.
• Force generic entrants into narrower design-around solutions or limit strengths/labeling.
• Increase litigation and settlement complexity, raising costs and delaying entry.

---

Is Talzenna exposed to biosimilar risk, or is it purely a small-molecule generic risk?

Talzenna (talazoparib) is a small-molecule drug, so the generic risk framework applies, not biosimilar exclusivity or biosimilar patent litigations. Investment risk focuses on ANDAs and Paragraph IV challenges rather than biosimilar pathways.

---

What manufacturing and IP barriers could slow generic launch of Talzenna (talazoparib)?

Practical barriers

Even where patents expire, generic launches can be delayed by:

• API supply chain constraints and quality system readiness.
• Bioequivalence study design and bridging strategy.
• Any remaining formulation process claims that could block specific manufacturing routes.
• Regulatory review timelines for complex manufacturing changes.

Economics

Barriers that slow entry reduce the speed of price decline, supporting revenue and margins. If barriers are minimal, generics can erode sales quickly after exclusivity ends.

---

Key Takeaways

• Talzenna’s investment fundamentals depend on a patent stack that protects not only talazoparib as an active ingredient but also formulation and method-of-use claims aligned to clinical practice.
• Generic entry risk is driven by Orange Book listing density and the survival of method-of-use and formulation patents, not by a single expiration date.
• Litigation and settlement outcomes determine whether generic substitution is delayed by years or accelerates sharply near the end of the patent calendar.
• Competitive dynamics within the PARP inhibitor class can shift revenue irrespective of patent status, so valuation requires dual-factor modeling: exclusivity timeline plus market share trajectory.
• Talzenna faces small-molecule generic risk via ANDAs and Paragraph IV challenges, not biosimilar risk.

---

FAQs

1) How do method-of-use patents change Talzenna’s generic launch timing?

They can delay full-label substitution even after composition/formulation protection ends by blocking generics that attempt to market for label-matching indications.

2) What is the main patent category investors should watch for Talzenna (talazoparib)?

Method-of-use and formulation listings near the end of the term, because they tend to determine whether ANDA entrants can launch with the same clinical positioning.

3) What settlement structures are most value-relevant for Talzenna (talazoparib)?

Agreements that set a date-certain launch delay for first ANDA, allow or restrict authorized generics, and define carve-out labels.

4) If an ANDA filer uses label-carve-outs for Talzenna, how does that affect sales erosion?

Carve-outs can reduce addressable patient populations for the generic, slowing revenue decline for Talzenna relative to a full-label substitution scenario.

5) Does Talzenna’s formulation protection usually extend beyond the API substance patents?

Often yes in PARP programs where solid-state, dissolution, and excipient-specific improvements are separately patented; the investment implication is a longer “time to generic parity.”

---

References (APA)

1. FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approval Reports and Labeling for Talzenna (talazoparib). U.S. Food and Drug Administration.